Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: A pharmacokinetic interaction study

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 199-208

  Ignjatovic, Anita Rakic ^a   Miljkovic, Branislava ^b   Todorovic, Dejan ^b   Timotijevic, Ivana ^b   Pokrajac, Milena ^b  

^a Medicines and Medical Devices Agency of Serbia   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Carbamazepine; Depression; Interaction; Moclobemide; Pharmacokinetics; Valproic acid

Indexed keywords

4 [2 (4 CHLOROBENZAMIDO)ETHYL]MORPHOLINE 4 OXIDE; 4 CHLORO N [2 (3 OXOMORPHOLINO)ETHYL]BENZAMIDE; AMLODIPINE; ATENOLOL; BROMAZEPAM; CARBAMAZEPINE; CEFALEXIN; CYTOCHROME P450 2C19; DIAZEPAM; ENALAPRIL; FAMOTIDINE; LORAZEPAM; MOCLOBEMIDE; NIFEDIPINE; NITRAZEPAM; PROPRANOLOL; RANITIDINE; VALPROIC ACID;

ADULT; AGITATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DEPRESSION; DOSE TIME EFFECT RELATION; DROWSINESS; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MONOTHERAPY; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RATING SCALE; SEXUAL DYSFUNCTION; SIDE EFFECT; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; CARBAMAZEPINE; CASE-CONTROL STUDIES; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MOCLOBEMIDE; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 61349164772     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03326.x     Document Type: Article

References (43)

1. Fitton A, Faulds D, Goa KL. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 1992 43 : 561 96.
2. Fulton B, Benfield P. Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs 1996 52 : 450 74.
3. Hilton S, Jaber B, Rauch R. Moclobemide safety: monitoring a newly developed product in the 1990s. J Clin Psychopharmacol 1995 15 (Suppl. 2 76S 83S.
4. Bonnet U. Moclobemide: therapeutic use and clinical studies. CNS Drug Rev 2003 9 : 97 140.
5. Jauch R, Griesser E, Oesterhelt G, Arnold W, Meister W, Ziegler WH, Guentert TW. Biotransformation of moclobemide in humans. Acta Psychiatr Scand 1990 360 (Suppl. 87 90.
6. Mayersohn M, Guentert TW. Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide. Clin Pharmacokinet 1995 29 : 292 332.
7. Bonnet U. Moclobemide: evolution, pharmacodynamic and pharmacokinetic properties. CNS Drug Rev 2002 8 : 283 308.
8. Guentert TW, Tucker G, Korn A, Pfefen JP, Haefelfinger P, Schoerlin MP. Pharmacokinetics of moclobemide after single and multiple oral dosing with 150 milligrams 3 times daily for 15 days. Acta Psychiatr Scand 1990 360 (Suppl. 91 3.
9. Shelton RC. Mood-stabilizing drugs in depression. J Clin Psychiatry 1999 60 (Suppl. 5 37 40.
10. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: A placebo-controlled study. J Affect Disord 2005 85 : 259 66.
11. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproic acid as an antidepressant in the major depressive disorder. Psychopharmacol Bull 1996 32 : 647 52.
12. Davis LL, Ryan W, Adinoff B, Petty F. A comprehensive review of the psychiatric use of valproate. J Clin Psychopharmacol 2000 20 : 1S 17S.
13. Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L. Mood stabilizer augmentation in apparently 'unipolar' MDD: predictors of response in the naturalistic French national EPIDEP study. J Affect Disord 2005 84 : 243 9.
14. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 2002 12 : 255 60.
15. Ciusani E, Zullino DE, Eap CB, Brawand-Amey M, Brocard M, Baumann P. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol 2004 18 : 559 66.
16. Stupaeck CH, Barnas C, Schwitzer J, Fleischhacker WW. Carbamazepine in the prophylaxis of major depression: a 5-year follow-up. J Clin Psychiatry 1994 55 : 146 50.
17. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006 61 : 246 55.
18. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003 2 : 473 81.
19. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002 43 (Suppl. 2 37 44.
20. Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol 2005 28 : 96 101.
21. Wen X, Wang JS, Kvistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001 52 : 547 53.
22. Spina E, Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007 100 : 4 22.
23. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003 17 : 517 38.
24. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001 104 : 104 9.
25. Amrein R, Guetert TW, Dingemanse J, Lorscheid T, Stabl M, Schmid-Burgk W. Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies. Psychopharmacology 1992 106 : S24 31.
26. Rakic A, Miljkovic B, Pokrajac M, Vucicevic K. High-performance liquid chromatographic method for the determination of moclobemide and its two major metabolites in human plasma. J Pharm Biomed Anal 2007 43 : 1416 22.
27. Carney MWP, Sheffield BF. Depression and the Newcastle Scales: their relationship to Hamilton's scale. Br J Psychiatry 1972 121 : 35 40.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960 23 : 56 62.
29. Guy W (ed.). Clinical Global Impressions. In : ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No ADM 76-338). Rockville, MD : US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976 : 218 22.
30. Holford NHG, Guentert TW, Dingemanse J, Banken L. Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor. Br J Clin Pharmacol 1994 37 : 433 9.
31. Gram LF, Guentert TW, Grange S, Vistisen K, Brosen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP1A2: a panel study. Clin Pharmacol Ther 1995 57 : 670 7.
32. Zimmer R, Gieschke R, Fischbach R, Gasic S. Interaction studies with moclobemide. Acta Psychiatr Scand 1990 360 : 84 6.
33. Yu KS, Yim DS, Cho JY, Park SS, Park JY, Lee KH, Jang IJ, Yi SY, Bae KS, Shin SG. Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001 69 : 266 73.
34. Hoskins J, Shenfield G, Murray M, Gross A. Characterization of moclobemide N-oxidation in human liver microsomes. Xenobiotica 2001 31 : 387 97.
35. Cashman JR, Zhang J. Human flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol 2006 46 : 65 100.
36. Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, Nayak RN. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1997 38 : 324 33.
37. Yukawa E, Nonaka T, Yukawa M, Higuchi S, Kuroda T, Goto Y. Pharmacoepidemiologic investigation of clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. J Clin Pharm Ther 2003 28 : 497 504.
38. Bertilsson L, Tybring G, Widén J, Chang M, Torbjörn T. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol 1997 44 : 186 9.
39. Lakehal F, Wurden CJ, Kalhorn TF, Levy RH. Carbamazepine and oxcarbamazepine decrease phenytoin metabolism through inhibition of CYP2C19. Epilepsy Res 2002 52 : 79 83.
40. Ono S, Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Furukori H, de Vries R, Kaneko S. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology 2002 162 : 50 4.
41. Ucar M, Neuvonen M, Luurila H, Dahlqvist R, Neuvonen PJ, Mjörndal T. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Pharmacol 2004 59 : 879 82.
42. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. Antidepressant effects of carbamazepine. Am J Psychiatry 1986 143 : 29 34.
43. Dingemanse J, Wood N, Guentert T, Øie S, Ouwerkerk M, Amrein R. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology 1998 140 : 164 72.